cromolyn sodium has been researched along with sulindac in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Dykewicz, MS | 1 |
1 review(s) available for cromolyn sodium and sulindac
| Article | Year |
|---|---|
Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management.
Topics: Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Baclofen; Cough; Cromolyn Sodium; Humans; Hypertension; Muscle Relaxants, Central; Sulindac | 2004 |
2 other study(ies) available for cromolyn sodium and sulindac
| Article | Year |
|---|---|
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |